Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

Nonsignificant increase seen from 2023; 11.6% of adults aged 18 to 64 and 5.1%of children aged 0 to 17 were uninsured in 2024.

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.

This pull out will cost 100s of thousands of children’s lives a year, and RFK Jr. will be personally responsible,” said Atal Gawande.

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

The ACIP voted to remove thimerosal from influenza vaccines in all age groups and pregnancy. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ...

The phase 3 trial evaluated fenfluramine when used as an adjunctive therapy for the treatment of uncontrolled seizures in children and adults aged 1 year to 35 years with CDD.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Direct access to Wegovy® (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.